Our new review paper about Pathway-Centric PTM Data Analysis is out this week in #Proteomics!
We cover databases, enrichment tools, software for pathway reconstruction, and full-fledged platforms that help to interpret high-throughput PTM datasets.
Check it out here: doi.org/10.1002/pmic...

They DecryptED all the KRAS small molecule inhibitors! Including cysteine enrichments! proteomicsnews.blogspot.com/2025/08/decr...

Measuring & modeling nucleic acids is very useful and needed.

Yet, it provides a partial view.

It misses many biological processes, from signal transduction and metabolic fluxes, through enzyme activities to therapeutic effects.

bsky.app/profile/slav...

@aithyra.bsky.social Opening Symposium "AI for Life Science" with Nobel Laureate Frances Arnold as keynote speaker in addition to an outstanding line up of speakers on a variety of topics across biological scales and data modalities.

Registration is now open at cemm.at/aithyra-symp...

🚨Our new paper is online🚨
We use zero-distance⚡photo-crosslinking⚡to reveal direct protein-DNA interactions in living cells, enabling quantitative analysis of the DNA-interacting proteome on a timescale of minutes. #DNA #Chromatin #Proteomics
www.cell.com/cell/fulltex...

Key takeaways:
a) every second HDAC inhibitor with a phenylhydroxamic warhead inhibits MBLAC2
b) NME1-4 and HINT1 are now targetable with small molecule inhibitors
c) chemoproteomics is always good for surprises 🙂

We characterized HINT1 and NME1-4 inhibition with enzyme activity assays, molecular docking, and co-crystal structures.

As often seen with chemoproteomic approaches, we made some unexpected but exciting findings: several molecules bound to the yet undrugged proteins NME1-4 and HINT1.

Having profiled over 100 molecules, we derive rules for which HDAC pharmacophores are prone to inhibit MBLAC2. We also found nanomolar MBLAC2 inhibitors with >30-100-fold selectivity over HDACs.

Here, we profiled a hand-picked library of metalloenzyme inhibitors. This uncovered several unreported off-targets of HDAC inhibitors and confirmed MBLAC2 as a frequent off-target, also for purportedly selective inhibitors such as SW-100.

Using a chemoproteomic competition assay, we previously identified MBLAC2 as off-target of more than 20/50 profiled HDAC inhibitors (www.nature.com/articles/s41...)

Paper alert!
We report the first inhibitors for nucleoside kinases NME1-4 and for the nucleotide-binding protein HINT1.
On top, we provide probes for MBLAC2, an off-target of every second (!) hydroxamic acid-based HDAC inhibitor!
tinyurl.com/yh92vh6b
👇🧵

One algorithm to rule them all? CHIMERYS bridges the gap — DDA,DIA and PRM — together at last!
With #CHIMERYS, we can now directly compare DDA and DIA data — 🍎 to 🍎 finally made possible.
doi.org/10.1038/s41592-025-02663-w
#KusterLab #WilhelmLab #MSAID #Proteomics

🚨 Hiring Alert – Senior Scientist (Biology) 🚨
My lab is looking for a senior scientist to lead functional genomics efforts and decode how small molecules reshape biology
🧬 Lead screens
🤝 Collaborate with top-tier AI/chemistry/biology minds

Interested? then apply: cemm.onlyfy.jobs/job/t7lhh1kz

🚨 Rational discovery of VHL molecular glues. New Preprint from @amgen.bsky.social Induced Proximity group led by postdoc Jonathan Bushman reports the discovery of a VHL molecular glue degrader of GEMIN3 by Picowell RNA-seq. Read on for details. 🧵1/8 www.biorxiv.org/content/10.1...

Less than 3 weeks left⏳Register by April 7 for the #Ubiquitin & Friends Symposium, May 8-9, in beautiful Vienna!
Fantastic guest speakers, open slots for short talks, flash talks& posters: Great opportunity for students & #ECRs! Register soon to save your spot➡️ www.protein-degradation.org/symposium/

Did you recently complete a ChemBio/MedChem PhD (non-UK) and are looking for the next challenge? I am seeking a prospective applicant for a Newton Fellowship with an exciting project in targeted protein dephosphorylation! Please reach out to [email protected]
royalsociety.org/grants/newto...

Today in @nature.com we share our back-to-back stories with Ning Zheng’s lab revealing chemical-genetic convergence between a molecular glue degrader & E3 ligase cancer mutations. 1/5